Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Keratins and desmosomal proteins: Utility for molecular subtype identification in muscle-invasive bladder cancer.

Virchows Archiv : an international journal of pathology·2026

Same author

Complete radiographic response to immunotherapy in a patient with metastatic anaplastic thyroid cancer - a case report and review of the literature.

Frontiers in oncology·2026

Same author

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial.

Nature cancer·2026

Same author

Integration of Patient-Reported Outcome Measures in Clinical Practice for Head and Neck Cancer Patients: A Cross-Sectional Survey.

Current oncology (Toronto, Ont.)·2026

Same author

Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

International Consensus on Severe Lung Cancer-The Second Edition.

Translational lung cancer research·2026

Search research articles

Related Experiment Video

Updated: Jun 29, 2025

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

Heterogeneity in precision oncology.

Bartłomiej Tomasik¹, Filip Garbicz^2,3,4, Marcin Braun⁵

¹Department of Oncology and Radiotherapy, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.

Cambridge Prisms. Precision Medicine

|March 29, 2024

Summary

This summary is machine-generated.

Precision oncology offers personalized cancer treatment, but tumor heterogeneity poses challenges. Advanced tools like next-generation sequencing and liquid biopsies are key to overcoming these limitations for better outcomes.

Keywords:

cancer genomics precision oncology proteomics tumour heterogeneity

More Related Videos

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Related Experiment Videos

Last Updated: Jun 29, 2025

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Area of Science:

Oncology
Genomics
Cancer Biology

Background:

Precision oncology aims to tailor cancer treatments to individual patients.
Genomic and acquired tumor heterogeneity complicates treatment effectiveness and increases toxicity.
Limitations affect both systemic therapies and radiotherapy in non-invasive cancer treatment.

Purpose of the Study:

To review the current status of precision oncology in solid tumors.
To focus on the impact of tumor heterogeneity and genomic features on systemic therapies and radiation.
To discuss novel tools for overcoming challenges in precision oncology.

Main Methods:

Review of current literature on precision oncology.
Analysis of the impact of tumor heterogeneity and genomic features.
Discussion of advanced tools including next-generation sequencing and liquid biopsies.

Main Results:

Tumor heterogeneity significantly impacts the effectiveness of systemic therapies and radiotherapy.
Genomic patient features are crucial for personalizing treatment strategies.
Novel tools show promise in addressing the complexities of tumor heterogeneity.

Conclusions:

Understanding and addressing tumor heterogeneity is essential for advancing precision oncology.
Personalized treatment strategies leveraging genomic data can revolutionize cancer care.
Next-generation sequencing and liquid biopsies are vital for overcoming current limitations.